Troy Wichterman Sells 987 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The shares were sold at an average price of $27.20, for a total value of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The stock was sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total value of $20,696.10.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $27.69 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The business has a 50-day moving average of $25.99 and a 200-day moving average of $24.29. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88.

Analyst Upgrades and Downgrades

BLFS has been the subject of several research analyst reports. Northland Securities upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday. Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. KeyCorp lifted their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen upped their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright dropped their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and an average price target of $29.43.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Mutual of America Capital Management LLC bought a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $8,592,000. Rockefeller Capital Management L.P. raised its position in BioLife Solutions by 81.3% during the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after acquiring an additional 262,504 shares in the last quarter. State Street Corp raised its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in BioLife Solutions by 261.5% in the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after acquiring an additional 92,021 shares during the last quarter. Finally, Fred Alger Management LLC increased its stake in shares of BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after purchasing an additional 88,840 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.